Sovantinib has dual antiangiogenetic mechanisms and mediates the immune microenvironment, preventing tumour neovascularization by inhibiting VEGFR1/2/3 and the fibroblast growth factor receptor (FGFR1), as well as by inhibiting colony stimulating factor-1 receptor (CSF-1R), thereby reducing the number of M2-type tumour-associated macrophages (TAMs) and regulating the immune response to tumour cells (20). Here, FLT1 is linked to neoplasm.